Fibroblast Hypersensitivity in Fanconi Anemia
The patient's fibroblasts show hypersensitivity to DNA cross-linking agents because they have defective DNA interstrand cross-link (ICL) repair due to pathogenic variants in Fanconi anemia pathway genes, and fibroblasts are the preferred diagnostic tissue when peripheral blood testing yields false-negative results due to somatic mosaicism in the lymphocyte compartment. 1
Why Fibroblasts Are Abnormal
The fundamental defect in FA fibroblasts involves multiple DNA repair abnormalities:
Deficient ICL repair: FA fibroblasts cannot properly produce endonucleolytic incisions at sites of DNA interstrand cross-links, specifically showing defective incisions on both the 3'- and 5'-sides of cross-link sites 2
Impaired DNA double-strand break repair: FA fibroblasts from complementation groups A, C, D2, and G rejoin linearized plasmids with significantly decreased efficiency (approximately 10-fold reduction) compared to normal fibroblasts 3
Dysregulated homologous recombination: FA fibroblasts (groups A, C, and G) demonstrate 10-fold elevated homologous recombination activity with correspondingly elevated RAD51 protein levels, indicating loss of normal DNA repair coordination 4
Failure to suppress DNA synthesis after damage: Unlike normal cells, FA fibroblasts fail to decrease their rates of replicative DNA synthesis following DNA cross-linking agent exposure, leading to prolonged G2 phase and accumulation of unrepaired damage 5
Why Peripheral Blood Testing Can Be False-Negative
The chromosomal breakage test can be falsely negative in peripheral blood due to somatic mosaicism in the lymphocyte compartment 6:
- T-lymphocytes used in standard DEB/MMC testing may have undergone spontaneous reversion mutations that restore FA pathway function
- This creates a mixed population where reverted cells have selective growth advantage and predominate in blood
- The degree of mosaicism can be quantitatively estimated but may be sufficient to mask the diagnosis 6
Diagnostic Approach When Blood Testing Is Negative
Fibroblast testing should be performed when clinical suspicion for FA remains high despite negative peripheral blood chromosomal breakage studies 1:
- Obtain skin biopsy for fibroblast culture
- Perform chromosomal breakage analysis on cultured fibroblasts using mitomycin C or diepoxybutane exposure 1, 6
- Fibroblasts are less likely to harbor revertant mutations compared to hematopoietic cells
- Follow with germline sequencing to identify the specific FA gene involved 1
Clinical Implications
The confirmed FA diagnosis has critical management implications:
Cancer surveillance: Begin annual HNSCC evaluation by otolaryngologist starting in early adolescence, monthly oral self-examinations, biannual dental examinations, and annual gynecologic examinations for females 1
Bone marrow monitoring: Perform baseline bone marrow aspirate and biopsy at diagnosis, then annual bone marrow evaluation with more frequent CBC monitoring, as over 95% develop bone marrow failure 1
Avoid DNA-damaging agents: Standard myeloablative chemotherapy dosing must be avoided; use reduced-intensity conditioning for hematopoietic cell transplantation 1
Cancer risk quantification: By age 50, cumulative incidence is approximately 50% for MDS, 10% for leukemia, and 20-30% for solid tumors 1
Common Pitfall
Do not exclude FA diagnosis based solely on negative peripheral blood chromosomal breakage testing, especially when physical findings or family history suggest FA 1. The absence of the classic triad (abnormal skin pigmentation, short stature, skeletal malformations) does not exclude FA, as up to one-third of patients have no physical anomalies 1. Proceed directly to fibroblast testing when clinical suspicion persists.